← All trials
NCT03610061
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2018
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Austin HealthLead sponsor
- AstraZenecaCollaborator
- Austin HealthReponsible party - principal investigator
- Austin HealthOverall official - principal investigator
- Olivia Newton-John Cancer Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.